日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases.

鲁索替尼介导的 JAK2 反常过度磷酸化是由于激活环酪氨酸免受磷酸酶的侵害所致

Gorantla Sivahari P, Oelschläger Lorenz, Prince Gerin, Osius Jasmin, Kolluri Suresh Babu, Maluje Yamil, Fähnrich Anke, Ernst Nancy, Barbosa Gulde Alanis, Ludwig Ralf Joachim, Gemoll Timo, Fliedner Stephanie, Walter Wencke, Haferlach Torsten, Gebauer Niklas, Busch Hauke, Duyster Justus, von Bubnoff Nikolas

Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma

分子肿瘤委员会:在肺腺癌病例中,通过鉴定和功能验证新的ALK耐药突变,进行分子水平调整治疗

Arndt, Annette; Neumann, Christian; Riecke, Armin; Bauer, Arthur; Müller, Matthias; Wölfle-Guter, Manuela; Grunert, Michael; Busch, Hauke; Künstner, Axel; von Bubnoff, Nikolas; Fliedner, Stephanie; Greinert, Dina; Osius, Jasmin; Nagarathinam, Kumar; Steinestel, Konrad; Gorantla, Sivahari Prasad; Gebauer, Niklas; Witte, Hanno M